Dedifferentiated chondrosarcoma

Summary

Dedifferentiated chondrosarcoma (MONDO:0005013) is a disease and 4 clinical trials. Top therapeutic interventions include cyclophosphamide anhydrous, lifileucel, and vismodegib. A subtype of bone chondrosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	dedifferentiated chondrosarcoma
Mondo ID	MONDO:0005013
EFO	EFO:0000394
DOID	DOID:0081247
NCIT	C6476
UMLS	C0862878
MedGen	209021
GARD	0024142
Is cancer (heuristic)	no

Also known as: DDCHS · Dedifferentiated chondrosarcoma

Data availability: 12 cell lines.

Disease family

This is a subtype of bone chondrosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › bone cancer › bone chondrosarcoma › dedifferentiated chondrosarcoma

Related subtypes (2): periosteal chondrosarcoma, clear cell chondrosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01267955	PHASE2	ACTIVE_NOT_RECRUITING	Vismodegib in Treating Patients With Advanced Chondrosarcomas
NCT03449108	PHASE2	ACTIVE_NOT_RECRUITING	LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
NCT04458922	PHASE2	ACTIVE_NOT_RECRUITING	Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
NCT02821507	PHASE2	COMPLETED	Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPHOSPHAMIDE ANHYDROUS	4	2
LIFILEUCEL	4	1
VISMODEGIB	4	1